Profile data is unavailable for this security.
About the company
Seelos Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in the development of products that address significant unmet needs in Central Nervous System (CNS) disorders and other rare disorders. The Company operates under one segment which develops pharmaceutical products. The Company's programs include SLS-002 for the potential treatment of acute suicidal ideation and behavior (ASIB) in patients with major depressive disorder (MDD) and SLS-005 for the potential treatment of amyotrophic lateral sclerosis (ALS) and spinocerebellar ataxia (SCA). SLS-002 is intranasal racemic ketamine with two investigational new drug applications (INDs). SLS-005 is used for the potential treatment of Sanfilippo Syndrome. SLS-005 is IV trehalose, a protein stabilizer that crosses the blood-brain barrier and activates autophagy and the lysosomal pathway. The Company's ongoing preclinical programs include SLS-004, SLS-006, and SLS-007.
- Revenue in USD (TTM)1.97m
- Net income in USD-27.12m
- Incorporated1987
- Employees10.00
- LocationSeelos Therapeutics Inc300 PARK AVENUE, 2ND FLOORNEW YORK 10022United StatesUSA
- Phone+1 (646) 293-2100
- Fax+1 (858) 436-8155
- Websitehttps://seelostherapeutics.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Actavia Life Sciences Inc | 0.00 | -406.65k | 1.23m | 1.00 | -- | -- | -- | -- | -0.0005 | -0.0005 | 0.00 | -0.0028 | 0.00 | -- | -- | 0.00 | -805.97 | -158.17 | -- | -- | -- | -- | -- | -- | -- | -5.63 | -- | -- | -- | -- | -547.04 | -- | -- | -- |
| Dermata Therapeutics Inc | 0.00 | -8.69m | 1.33m | 8.00 | -- | 4.13 | -- | -- | -24.67 | -24.67 | 0.00 | 0.5717 | 0.00 | -- | -- | 0.00 | -120.05 | -- | -146.08 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 18.90 | -- | -- | -- |
| Salarius Pharmaceuticals Inc | 0.00 | -8.92m | 1.36m | 2.00 | -- | 0.3362 | -- | -- | -21.71 | -21.71 | 0.00 | 6.77 | 0.00 | -- | -- | 0.00 | -119.38 | -69.27 | -193.68 | -79.89 | -- | -- | -- | -675.70 | -- | -- | 0.031 | -- | -- | -- | 60.32 | -- | -- | -- |
| Manuka Inc | 671.00k | -1.14m | 1.46m | 4.00 | -- | -- | -- | 2.17 | -0.0128 | -0.0128 | 0.0066 | -0.0124 | 2.41 | 0.9412 | 37.28 | 167,750.00 | -410.43 | -463.75 | -- | -- | 88.08 | -- | -170.04 | -732.15 | 0.0194 | -- | -- | -- | -- | -- | -854.23 | -- | -- | -- |
| 180 Life Sciences Corp | 0.00 | -16.24m | 1.47m | 4.00 | -- | -- | -- | -- | -41.54 | -41.54 | 0.00 | -1.12 | 0.00 | -- | -- | 0.00 | -176.90 | -42.39 | -354.57 | -56.41 | -- | -- | -- | -- | -- | -385.88 | -- | -- | -- | -- | 48.52 | -- | -- | -- |
| Drazcanna Inc | 2.05m | -5.71m | 1.47m | -- | -- | -- | -- | 0.7192 | -0.7024 | -0.7024 | 0.2492 | 0.1004 | 0.685 | -- | 23.88 | -- | -191.19 | -- | -643.20 | -- | -11.20 | -- | -279.10 | -- | -- | -33.04 | 0.2445 | -- | -- | -- | -- | -- | -- | -- |
| Virpax Pharmaceuticals Inc | 0.00 | -16.89m | 1.58m | 7.00 | -- | -- | -- | -- | -14.42 | -14.42 | 0.00 | -1.04 | 0.00 | -- | -- | 0.00 | -156.21 | -87.52 | -241.52 | -116.56 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 29.84 | -- | -- | -- |
| Seelos Therapeutics Inc | 1.97m | -27.12m | 1.59m | 10.00 | -- | -- | -- | 0.804 | -44.59 | -44.59 | 2.16 | -17.36 | 0.1449 | -- | 2.24 | 131,600.00 | -198.99 | -180.05 | -- | -386.76 | -- | -- | -1,373.61 | -9,612.88 | -- | -- | -- | -- | -- | -- | 48.48 | -- | -- | -- |
| CNS Pharmaceuticals Inc | 0.00 | -17.46m | 1.76m | 3.00 | -- | -- | -- | -- | -179.17 | -179.17 | 0.00 | -20.76 | 0.00 | -- | -- | 0.00 | -384.86 | -132.47 | -- | -185.75 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -23.42 | -- | -- | -- |
| Hi-Great Group Holding Co | 101.27k | -113.56k | 1.78m | -- | -- | -- | -- | 17.58 | -0.0011 | -0.0011 | 0.001 | -0.0011 | 0.7887 | 0.8027 | -- | -- | -88.44 | -- | -- | -- | 48.60 | -- | -112.14 | -- | 0.0197 | -48.81 | -- | -- | -47.32 | -- | -3,789.70 | -- | -- | -- |
| Panbela Therapeutics Inc | 0.00 | -27.26m | 1.78m | 7.00 | -- | -- | -- | -- | -20.38 | -20.38 | 0.00 | -0.6563 | 0.00 | -- | -- | 0.00 | -201.94 | -215.89 | -809.38 | -476.38 | -- | -- | -- | -- | -- | -161.79 | 4.16 | -- | -- | -- | 27.68 | -- | -- | -- |
| Windtree Therapeutics Inc | 0.00 | -5.96m | 1.88m | 15.00 | 0.1716 | 0.1052 | -- | -- | 18.53 | 18.53 | 0.00 | 30.23 | 0.00 | -- | -- | 0.00 | -18.26 | -44.51 | -20.72 | -48.38 | -- | -- | -- | -94,533.34 | -- | -- | 0.00 | -- | -- | -- | 48.25 | -- | -- | -- |
| PaxMedica Inc | 0.00 | -18.15m | 1.94m | 6.00 | -- | 1.57 | -- | -- | -11.19 | -11.19 | 0.00 | 0.1594 | 0.00 | -- | -- | 0.00 | -474.77 | -755.77 | -781.78 | -- | -- | -- | -- | -- | -- | -3,015.03 | 0.00 | -- | -- | -- | -23.56 | -- | -- | -- |
| Galmed Pharmaceuticals Ltd | 0.00 | -6.36m | 1.97m | 3.00 | -- | 0.1462 | -- | -- | -2.83 | -2.83 | 0.00 | 2.12 | 0.00 | -- | -- | 0.00 | -43.37 | -45.06 | -51.38 | -50.79 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 61.31 | -- | -- | -- |
Data as of Jul 05 2024. Currency figures normalised to Seelos Therapeutics Inc's reporting currency: US Dollar USD
12.19%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Wealth Effects LLCas of 31 Mar 2024 | 58.33k | 2.28% |
| AdvisorShares Investments LLCas of 31 Mar 2024 | 57.84k | 2.27% |
| Tontine Associates LLCas of 31 Mar 2024 | 53.62k | 2.10% |
| Balyasny Asset Management LPas of 31 Mar 2024 | 47.41k | 1.86% |
| The Vanguard Group, Inc.as of 31 Mar 2024 | 35.11k | 1.38% |
| Modera Wealth Management LLCas of 31 Mar 2024 | 19.70k | 0.77% |
| Morgan Stanley Smith Barney LLC (Investment Management)as of 31 Mar 2024 | 15.69k | 0.61% |
| Geode Capital Management LLCas of 31 Mar 2024 | 12.80k | 0.50% |
| BlackRock Fund Advisorsas of 31 Mar 2024 | 7.00k | 0.27% |
| Strategic Family Wealth Counselors LLCas of 31 Mar 2024 | 3.75k | 0.15% |
More ▼
Data from 31 Mar 2024 - 31 Mar 2024Source: FactSet Research Systems Inc.
